Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Heterogeneous catalysts for electro-Fenton degradation of cytostatic drug cytarabine.
Chemosphere
February 2025
Université Gustave Eiffel, Laboratoire Géomatériaux et Environnement EA 4508, 77454, Marne-la-Vallée, Cedex 2, France. Electronic address:
Article Synopsis
- A new bifunctional carbon felt cathode modified with reduced graphene oxide and iron oxide (rGO-FeO/CF) was created to generate hydroxyl radicals on-site, eliminating the need for external catalysts.
- The study focused on degrading the cytostatic drug cytarabine using two setups: the bifunctional cathode and a combination of a graphene-modified cathode with a magnetic heterogeneous Fenton catalyst.
- Results showed that the rGO-FeO/CF system could completely degrade 0.1 mM cytarabine in 18 minutes, achieving 98.2% mineralization after 4 hours, while the rGO/CF and CNT-FeO setup reached complete degradation in just
An Assessment of Surface Contamination and Dermal Exposure to 5-Fluorouracil in Healthcare Settings by UPLC-MS/MS Using a New Atmospheric Pressure Ionization Source.
Toxics
October 2024
Centre for Environment and Health, Department of Public Health and Primary Care, University of Leuven (KU Leuven), 3000 Leuven, Belgium.
5-Fluorouracil (5-FU) is a well-known cytostatic drug, which is often used in cancer treatments. Yet, it is also a very dangerous compound for people who are occupationally exposed to it for a long time, such as pharmacy employees, nurses and cleaning staff. We aimed to improve and implement a LC-MS/MS method for 5-FU quantification on surface contamination samples collected with swabs in a pharmacy department and outpatient nursing station of a university hospital.
View Article and Find Full Text PDFFuture Treatment Strategies for Cancer Patients Combining Targeted Alpha Therapy with Pillars of Cancer Treatment: External Beam Radiation Therapy, Checkpoint Inhibition Immunotherapy, Cytostatic Chemotherapy, and Brachytherapy.
Pharmaceuticals (Basel)
August 2024
Research Group Molecular Biology of Systemic Radiotherapy/Translational Radiotheranostics, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69120 Heidelberg, Germany.
Cancer is one of the most complex and challenging human diseases, with rising incidences and cancer-related deaths despite improved diagnosis and personalized treatment options. Targeted alpha therapy (TαT) offers an exciting strategy emerging for cancer treatment which has proven effective even in patients with advanced metastatic disease that has become resistant to other treatments. Yet, in many cases, more sophisticated strategies are needed to stall disease progression and overcome resistance to TαT.
View Article and Find Full Text PDFDisulfide Cross-Linked Polymeric Redox-Responsive Nanocarrier Based on Heparin, Chitosan and Lipoic Acid Improved Drug Accumulation, Increased Cytotoxicity and Selectivity to Leukemia Cells by Tumor Targeting via "Aikido" Principle.
Gels
February 2024
Faculty of Chemistry, Lomonosov Moscow State University, Leninskie Gory, 1/3, 119991 Moscow, Russia.
We have developed a micellar formulation of anticancer drugs based on chitosan and heparin grafted with lipoic and oleic acids that can release the cytotoxic cargo (doxorubicin) in response to external stimuli, such as increased glutathione concentration-a hallmark of cancer. Natural polysaccharides (heparin and chitosan) provide the pH sensitivity of the nanocarrier: the release of doxorubicin (Dox) is enhanced in a slightly acidic environment (tumor microenvironment). Fatty acid residues are necessary for the formation of nanoparticles (micelles) and solubilization of cytostatics in a hydrophobic core.
View Article and Find Full Text PDFZeolitic Imidazolate Framework (ZIF-8) Decorated Iron Oxide Nanoparticles Loaded Doxorubicin Hydrochloride for Osteosarcoma Treatment - in vitro and in vivo Preclinical Studies.
Int J Nanomedicine
January 2024
Department of Orthopedics, the Affiliated Hospital of Qingdao University, Qingdao, 266003, People's Republic of China.
Background: As a broad-spectrum antitumorigenic agent, doxorubicin (DOX) is commonly used as a chemotherapeutic drug for treating osteosarcoma (OS). Still, it is associated with significant cell toxicity and ineffective drug delivery, whereas the zeolite imidazolate framework is extensively applied in the biomedical field as a carrier owing to its favorable biocompatibility, high porosity, and pH-responsiveness. Therefore, we need to develop a drug delivery platform that can effectively increase the antitumorigenic effect of the loaded drug and concurrently minimize drug toxicity.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!